Posted by Michael Wonder on 16 Apr 2026
‘Trojan horse’ treatment recommended for people with multiple myeloma
16 April 2026 - Around 1,600 people a year in England with multiple myeloma are set to benefit from a new treatment option after we recommended belantamab mafodotin (Blenrep, GSK).
Our recommendation comes in final draft guidance and means the treatment can be offered on the NHS from today for people whose cancer has come back after previous therapy.
